UBS analysts maintained a Buy rating for Alvotech SA (NASDAQ:ALVO) with a steady price target of $18.00, representing a 41% ...

AbbVie Inc . (NYSE:ABBV), currently trading at $190.14, has demonstrated resilience and strategic foresight as it navigates the loss of exclusivity for its blockbuster drug Humira. The ...

The first shot taken at Medicaid, likely UnitedHealthcare coverage for Vertex's pain drug, and Optum’s wellness visit ad.

If you're a business owner, your car insurance won't cover a car, truck, van or other vehicle you use for work That's when you need commercial auto insurance. It provides the same protections as ...

AbbVie also says it expects company revenue this year to exceed its 2022 peak of $58 billion in just the second full year after losing U.S. patent protection for Humira. AbbVie up 4.5% premarket ...

The Boston icons, Affleck, Brady and Damon, formed a boy band and performed for Lopez in Dunkin's 2024 Super Bowl commercial Sabrina Weiss is the Editorial Assistant of PEOPLE's food department.

He emphasized the consistent outperformance of the ex-Humira platform, which grew over 18% annually and accelerated to 22% growth in Q4. The company projects mid-single-digit revenue growth in 2025, ...

The new 60-second ad turns up in Super Bowl LIX alongside commercials for parent company Anheuser-Busch InBev’s Stella Artois, Budweiser and Michelob Ultra. The characters would seem to be the ...

Budweiser unveiled its new 98-second commercial ad on Monday for the upcoming Super Bowl LIX called "First Delivery." It will feature a new young star — a Clydesdale foal that was born at its ...

Investing.com -- AbbVie (NYSE: ABBV) saw its shares jump more than 4% in premarket trading Friday after the company's profit guidance for the fiscal 2025 year exceeded analyst expectations, driven by ...

Quarterly sales of Humira declined 49% to $1.68 billion, a steeper fall than the $1.99 billion analysts expected, according ...

Skyrizi, Rinvoq sales expected to surpass $31 billion by 2027 Humira sales decline 49% due to cheaper biosimilar competitors AbbVie earns $2.16 per share in Q4, beats estimates Jan 31 (Reuters ...